Phase 1 Autism Spectrum Disorder Trial, Recruiting NCT07622316 Sponsor: Greater Atlanta Integrative Pediatrics Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Phase 1 Autism Spectrum Disorder Trial, Recruiting

NCT07622316
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children and adults aged 3 years or older may be considered.
  • People who have a confirmed diagnosis of Autism Spectrum Disorder (ASD), assessed using recognised diagnostic tools and guidelines.
  • People whose parent or guardian is willing to consider experimental treatments and follow the study's requirements.
  • People who are able to have the required blood tests done.
  • People who are able to attend all scheduled appointments for the study.

Who may not be able to join:

  • People who have severe allergies to the products being used in the study.
  • People who have significant medical conditions that are not well controlled.
  • People whose immune system is weakened or not functioning normally.
  • People who have a history of cancer or malignant disease.
  • People whose medication routine has been unstable in the 30 days before the study starts — for example, frequent changes to medications or regularly missed doses (the trial doctor will assess this on a case-by-case basis).
  • People who are pregnant or breastfeeding, where this applies.
  • People who have taken part in another interventional clinical trial within the past 30 days.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Maia Gaither, MD, Greater Atlanta Integrative Pediatrics

Phone: 4047513693

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Greater Atlanta Integrative Pediatrics
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 6

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov